HONG KONG DRUG LICENSING

Hong Kong Drug Licence FAQs

Search 500 Hong Kong drug licence FAQs on applications, personnel, premises, quality systems, ongoing regulation, renewals and acquisitions.

Information status: The original FAQ material dates from 2025 and is provided for topic-based reference; it does not represent an individual verification of all 500 FAQs against current rules. For application, fee, renewal, change, product or prescription requirements, please refer to the current official forms and guidance.

Official information from the Drug Office Official information from the Chinese Medicines Board

找到 50 条结果，第 1／3 页。每页显示 20 条；无需启用 JavaScript。

Thematic illustration for pharmaceutical licensing business queries and document organisation services — Discuss actual operating questions one-to-one to clarify the next decision.

Q301 · 对于香港的持牌批发商而言，建立一个有效的质量管理体系（QMS）为何至关重要？它的核心组成部分有哪些？独立链接

A Quality Management System (QMS) is a systematic approach designed to ensure the quality, safety and efficacy of medicines throughout the supply chain, from procurement and storage to distribution. For any business wishing to engage in pharmaceutical wholesale in Hong Kong, it is not only a basic compliance requirement but also the foundation of the business’s reputation and public health. An effective QMS systematically identifies, assesses and controls medicine quality risks, ensuring that all operations meet predefined standards and regulatory requirements. Its core components typically include a clear Quality Policy, a detailed Quality Manual, a complete set of Standard Operating Procedures (SOPs), a clear organisational structure and allocation of responsibilities, and a comprehensive records and data management system. By implementing a QMS, a business can continually improve its processes, increase operational efficiency and respond confidently to the stringent scrutiny of the Drug Office, Department of Health.

📘 Regulatory basis

The Pharmacy and Poisons Ordinance (Cap. 138) does not set out the details of a QMS provision by provision. However, the Code of Practice for Holders of Wholesale Dealer Licences for Poisons, made under the Ordinance, expressly requires licence holders to establish and maintain an effective quality system to ensure that medicines are handled in accordance with the requirements and to safeguard public health.

📗 Drew Tang's recommendations

When helping clients establish a QMS, Rengangyongsheng (Hong Kong) Limited always emphasises that it should be tailored to the business and operated continuously. Do not treat the QMS as a pile of documents to be left on a shelf. We recommend first conducting a gap analysis of existing processes against GDP, then setting practical quality objectives and SOPs. Once the system is established, regular internal audits and management reviews are essential to make it a “living” system that continually improves itself.

📕 Risk notice

An inadequate or non-existent QMS is one of the most serious warning signs for the Pharmacy and Poisons Board (PPB) during a review or inspection. This may not only result in a licence application being refused; a licensed business may also risk suspension or revocation of its licence. Any quality-related negligence could have catastrophic legal and financial consequences.

Q302 · 在编写药品批发业务的标准操作程序（SOPs）时，应遵循怎样的架构才能确保其清晰、合规且易于执行？独立链接

Standard Operating Procedures (SOPs) are the backbone of a Quality Management System, providing specific, consistent guidance for key operations. Professional, properly structured SOPs not only ensure consistency in staff operations but are also important documents for demonstrating a company’s compliance to the regulatory authorities. When drafting them, ensure that the content is comprehensive and logically clear. A standard SOP should include at least the following: document title, unique SOP number, version number, effective date, drafter/reviser, reviewer, approver, clearly stated “purpose” and “scope”, allocation of “responsibilities” among relevant personnel, a “procedure” described in specific steps, and attachments containing forms for the “records” to be completed during the operation. This structure ensures that the SOP is complete, traceable and authoritative, enabling it to provide genuine guidance in day-to-day work.

📘 Regulatory basis

The Drug Office, Department of Health’s Good Distribution Practice (GDP) for Pharmaceutical Products clearly requires licensed wholesalers to establish written SOPs for all critical activities that affect product quality, such as receipt, storage, picking, packing, transportation, handling of returned goods and product recalls.

📗 Drew Tang's recommendations

When drafting SOPs, always consider the perspective of the person carrying out the task. Use clear, concise language and avoid ambiguous wording. For complex processes, flowcharts, diagrams or checklists can make the steps easier to follow. Once the first draft is complete, it is best to have the employees who will carry out the SOP test it and provide feedback. All employees must also receive relevant SOP training, and training records must be retained; these are a key focus during inspections.

📕 Risk notice

Vague or outdated SOPs, or SOPs that staff do not follow consistently, are among the most common shortcomings identified during regulatory inspections. If inspectors find that actual practices do not match the SOPs, they will immediately question the seriousness of the company’s quality control. This may lead to a warning letter, a requirement to take corrective action or even more severe penalties.

Q303 · 香港的药品优良运销规范（GDP）对仓储设施的温湿度监控有何具体要求？我们应如何达标？独立链接

Good Distribution Practice (GDP) requirements for temperature and humidity control are very strict because improper storage conditions can directly affect the stability and efficacy of medicines. First, medicines must be stored according to the label instructions (such as “Store below 25°C” or “Refrigerate at 2–8°C”). The warehouse must be equipped with a sufficient number of calibrated temperature and humidity monitoring devices to record data continuously. Based on the results of a temperature mapping study, the probes should be strategically positioned at points in the warehouse representative of extreme temperatures (the highest and lowest). Data records should be reviewed regularly (for example, daily). Any deviation from the pre-set range must be documented, and corrective and preventive action (CAPA) taken immediately. Backup power and alarm systems should also be provided to deal with unexpected power outages or equipment failures.

📘 Regulatory basis

The Drug Office, Department of Health’s Good Distribution Practice for Pharmaceutical Products and its technical guidelines set out in detail the requirements for temperature and humidity control, monitoring, recording and calibration in storage areas. These requirements are intended to ensure that medicines remain under the conditions specified on their labels throughout storage.

📗 Drew Tang's recommendations

We strongly recommend that clients invest in an automated electronic temperature and humidity monitoring system that complies with 21 CFR Part 11. Such systems provide real-time data, remote alerts and tamper-proof electronic records, greatly reducing the burden and risks of manual record-keeping. Temperature mapping studies should take into account different scenarios, such as a fully loaded and empty warehouse, and summer and winter conditions, to ensure the study is comprehensive. Calibration services must be performed by an accredited third-party organisation.

📕 Risk notice

Incomplete temperature and humidity records, uncalibrated monitoring equipment, or failure to take any action in response to temperature deviations are serious GDP breaches. If discovered, the regulator may consider the quality of your stock of medicines unreliable, may require you to destroy the affected batches, and may take action against your licence. This is an area that must never be taken lightly.

Q304 · 什么是药品生产质量管理规范（GMP）？它与药品优良运销规范（GDP）有何区别和联系？独立链接

Good Manufacturing Practice (GMP) is a set of mandatory standards applicable throughout the medicine manufacturing process. It aims to ensure the consistent production of medicines that meet quality standards and regulatory requirements by strictly controlling key factors such as personnel, premises, equipment, materials, methods and the environment. Good Distribution Practice (GDP), by contrast, focuses on the supply chain after medicines leave the production line, including procurement, storage, transport and distribution. In brief, GMP governs “manufacture” and ensures products are “manufactured to the required standard”; GDP governs “distribution” and ensures that product quality does not deteriorate before compliant products reach the end user. Together, they form an integrated quality assurance system for medicines from the beginning to the end of the supply chain; both are closely linked and indispensable.

📘 Regulatory basis

In Hong Kong, GMP is primarily based on the GMP Guide published by the Pharmaceutical Inspection Co-operation Scheme (PIC/S), of which the Department of Health is a member. GDP follows the Department of Health Drug Office’s Good Distribution Practice Guide for Pharmaceutical Products. Both are important technical guidelines within the framework of the Pharmacy and Poisons Ordinance (Cap. 138).

📗 Drew Tang's recommendations

Although wholesalers are not directly involved in manufacturing, it is essential for them to understand GMP. GDP requires you to ensure that medicines procured are from manufacturers holding valid GMP certificates. Be sure to review suppliers’ evidence of GMP compliance. Your own GDP system should also interface effectively with the quality standards of upstream manufacturers. For example, when handling product complaints or recalls, it should work efficiently with the manufacturers’ GMP systems.

📕 Risk notice

As a wholesale dealer, procuring medicines from a source without GMP qualifications is a serious offence. This not only exposes your business to legal penalties but also places the public at significant risk from medicines. The regulator takes a zero-tolerance approach to such conduct. If discovered, your Wholesale Dealer Licence may be revoked immediately, and you may face criminal prosecution.

Q305 · 在质量管理体系中，记录保存（Record-Keeping）的具体要求是什么？需要保存多久？独立链接

In the pharmaceutical wholesale industry, complete records are the only way to demonstrate compliant operations and achieve product traceability. GDP requires clear, accurate and timely records of all key activities. These records must be sufficient to reconstruct the full “life history” of every batch of pharmaceutical products, from procurement, receipt, and putting into storage through storage, picking, sale and final dispatch. Records to be retained include, but are not limited to: purchase orders, invoices, receipt inspection records, inventory records, temperature and humidity monitoring records, sales orders, dispatch records, customer qualification documents, staff training records, internal audit reports, complaint handling records and recall records. All records should be kept securely and systematically and be available for inspection by the regulatory authorities at any time.

📘 Regulatory basis

The Good Distribution Practice (GDP) for Medicinal Products expressly requires all records relating to the distribution of medicines to be retained. As for the retention period, section 28 of the Pharmacy and Poisons Regulations (Cap. 138A) requires records of the sale and supply of poisons (the “poisons book”) to be kept for at least two years from the date of the last entry.

📗 Drew Tang's recommendations

Although the minimum retention period for poisons records under the regulations is two years, we generally recommend that clients keep all medicine-related transaction and quality records for at least one year after the medicines’ expiry date, as a precaution. For electronic record systems, data integrity, security and traceability must be ensured, with reliable backup and recovery procedures in place. In practice, clear records are valuable not only for inspections, but also for self-assessment, problem tracking and continuous improvement.

📕 Risk notice

Incomplete records or an inability to produce them is one of the most common and readily penalised deficiencies identified during inspections. If you cannot provide a complete medicine traceability chain, the regulatory authority may consider your management to be out of control and unable to assure medicine quality. Missing records may prevent effective action during an emergency, such as a product recall, magnify the risks and expose you to more serious legal liability.

Q306 · 如果需要召回（Recall）一个批次的药品，批发商应遵循怎样的程序？SOP中需要包含哪些关键步骤？独立链接

A medicine recall is a key risk response within the quality management system and requires a rapid, accurate and efficient response. Once you receive a recall notification from a manufacturer or regulatory authority, or discover a serious product quality problem yourself, you must immediately initiate the recall procedure. Your recall SOP should clearly define different recall classes (such as Class I, II and III) and specify the response time and action plan for each. Key steps include: 1. Immediately quarantine affected batches and stop their distribution; 2. promptly identify all customers who purchased the batches and the quantities distributed; 3. issue written recall notices to all relevant customers within the prescribed time; 4. arrange the return, receipt, segregation and handling of recalled medicines; 5. continuously monitor recall progress and report regularly to the manufacturer and Department of Health; 6. investigate the root cause and take corrective and preventive action (CAPA).

📘 Regulatory basis

The Drug Office, Department of Health’s Guidelines on Product Recall provide licensed wholesalers with detailed guidance on actions to take. The guidelines classify recalls according to the level of risk to public health and set out specific requirements for notification timelines, execution effectiveness and reporting.

📗 Drew Tang's recommendations

“Acting swiftly is essential” is the golden rule of recalls. We recommend that clients conduct mock recall exercises regularly to test and improve the effectiveness of their recall SOP and traceability system. Ensure that you have an accurate customer contact database readily available. During a recall, appointing a dedicated coordinator to manage internal and external communications can help prevent confusion. All communications, actions and decisions relating to the recall must be documented in detail for review.

📕 Risk notice

Delays or ineffective execution of a recall expose the public to unnecessary risks, which regulatory authorities will not tolerate. Failure to carry out an effective recall may result in substantial fines, revocation of the licence and even criminal prosecution of the relevant persons. An ineffective traceability system would be a critical weakness at such a time.

Q307 · 当收到客户关于药品质量的投诉时，正确的处理流程是怎样的？独立链接

Handling customer complaints is an important part of the QMS. It affects not only customer satisfaction but also provides an important channel for identifying potential product quality issues and system deficiencies. A compliant complaint-handling process should be clearly set out in an SOP. The process starts with a detailed record of all complaint information, including the complainant’s details, product name, batch number and specific complaint. A designated person should then conduct an initial assessment to determine whether the complaint involves an adverse drug reaction or a serious quality issue. Where possible, the customer should be asked to return a sample for examination. An internal investigation should then be conducted, including checks of retained samples from the relevant batch and storage and distribution records. If the complaint concerns a manufacturing defect, the manufacturer must be notified immediately. All investigations, findings and final decisions (such as a refund, replacement or a determination that the complaint is unfounded) must be documented in a written report, and the complainant must be informed of the outcome.

📘 Regulatory basis

The Good Distribution Practice (GDP) for Medicinal Products requires licensed wholesalers to establish written procedures for handling complaints, distinguish between complaints about product quality defects and other complaints, and investigate in collaboration with the manufacturer. All decisions and actions must be recorded and made available for inspection.

📗 Drew Tang's recommendations

Treat every complaint as a free “external audit”. We recommend that clients establish a complaint-trend analysis system and review complaint data regularly to identify recurring issues and drive systematic process improvements. Train staff to receive complaints professionally and politely and to record key information accurately. Retain detailed investigation records for every complaint involving a potential quality defect, regardless of the final investigation outcome.

📕 Risk notice

Ignoring or mishandling medicine quality complaints can turn a minor issue into a major crisis. If a serious quality issue that should have been identified is overlooked because complaints are poorly handled, resulting in harm to public health, the company may face extremely serious legal consequences. During inspections, the regulatory authorities will pay particular attention to complaint-handling records to assess whether your quality system is genuinely operating effectively.

Q308 · 什么是质量管理体系中的内部审核（Internal Audit）？它应该由谁来执行，频率如何？独立链接

An internal audit, also known as self-inspection, is a proactive, forward-looking quality assurance activity within a QMS. It is a systematic process, independent of the department being audited, to assess whether the company’s activities consistently comply with GDP requirements and its internal SOPs, and to identify opportunities for improvement. The audit should cover all areas related to medicine quality, including personnel, premises and facilities, equipment, documents and records, and operating procedures. A formal report must be issued after the audit, detailing deficiencies identified. The relevant departments must then develop and implement corrective and preventive action (CAPA). This is a key driver of the continuous improvement cycle.

📘 Regulatory basis

The Good Distribution Practice (GDP) for Medicinal Products expressly requires licensees to conduct regular self-inspections to monitor the implementation of and compliance with GDP principles, and to propose any necessary corrective measures. All self-inspection procedures and records must be documented.

📗 Drew Tang's recommendations

To ensure objectivity, internal auditors should have appropriate training and knowledge and be independent of the activities they audit. If internal resources are limited, you could consider engaging an independent external auditor, such as Rengangyongsheng (Hong Kong) Limited, which can often provide deeper, unbiased insights. We recommend conducting a comprehensive internal audit at least once a year, with more frequent audits for critical or new processes. Treating an internal audit as a “rehearsal”, rather than an “exam”, helps you get more value from it.

📕 Risk notice

Never conducting internal audits, or conducting them as a mere formality (for example, reporting “no deficiencies” every time), is a clear sign to regulators that the QMS is ineffective. It indicates that the company lacks a culture of self-criticism and continual improvement. If a regulatory inspection identifies numerous problems that should have been found and corrected through internal audits, the company may face more severe criticism and penalties.

Q309 · 在药品批发业务中，如何对供应链中的合作伙伴（如运输公司）进行有效的资质审核和管理？独立链接

Under GDP principles, a medicine wholesaler’s quality responsibilities do not end when certain activities, such as transport or storage, are outsourced. You must rigorously qualify and continuously monitor the performance of all partners involved in your supply chain. Before selecting a transport company, you must conduct due diligence to confirm that it can meet the specific requirements for transporting medicines, particularly medicines requiring cold-chain transport. The parties should sign a detailed Quality Agreement setting out their respective responsibilities for temperature control, security, handover procedures and emergency response. You should regularly review the transporter’s performance, for example by inspecting its vehicles, temperature-control equipment calibration records and temperature data during transport.

📘 Regulatory basis

Chapters 9, “Transportation”, and 7, “Outsourced Activities”, of the Good Distribution Practice (GDP) for Medicinal Products set out clear requirements on this. Licensees must control outsourced activities to avoid any adverse impact on the quality of medicines. All outsourced activities must be covered by a written contract clearly defining the responsibilities of each party.

📗 Drew Tang's recommendations

Do not choose a transport partner based on price alone. We recommend maintaining an Approved Supplier/Vendor List. Before adding any transport company to the list, conduct an on-site assessment and request relevant SOPs and training records. Quality agreements should be as detailed as possible and cover all foreseeable scenarios. For cold-chain transport, require the carrier to provide complete temperature records for each shipment, for review by your quality department.

📕 Risk notice

If your transport partner makes an error during transit (such as a break in the cold chain) that compromises the quality of the medicines, you, as the licensed wholesaler, will ultimately bear the legal and reputational responsibility. During a regulatory inspection, if you cannot provide evidence of effective management of the transport provider (such as qualification checks, quality agreements and performance evaluation records), you will be considered to have failed to fulfil your GDP responsibilities. This is a serious compliance deficiency.

Q310 · 对于需要冷链运输的药品，从接收、储存到发运的全过程，有哪些关键的质量控制点？独立链接

Cold-chain medicine management is a major focus of GDP and requires the specified temperature (usually 2-8°C) to be maintained without interruption throughout the supply chain. Key quality control points apply throughout. On receipt: immediately check the temperature data logger in the refrigerated container or vehicle to confirm that temperatures did not exceed the limits during transport, and check the outer packaging for signs of condensation or frost. During storage: use a dedicated cold room or refrigerator that has undergone temperature mapping and is continuously monitored, with an audible and visual alarm system and backup power. On dispatch: use validated insulated shippers and coolants, selecting the packaging configuration according to the estimated transport time and external ambient temperature. At handover, ensure that the recipient can transfer the medicines immediately to compliant refrigeration equipment.

📘 Regulatory basis

The Good Distribution Practice (GDP) for Medicinal Products has a dedicated and stringent chapter on handling temperature-sensitive medicines. Equipment, procedures and records must all demonstrate the ability to maintain cold chain integrity.

📗 Drew Tang's recommendations

We strongly recommend that clients conduct rigorous Performance Qualification (PQ) studies of the refrigerated packaging solutions they use, to ensure that the specified temperature is maintained even under simulated worst-case conditions (such as high summer temperatures and transport delays). Include a separate temperature data logger with every cold-chain shipment and require the customer to return the data to you on receipt, creating a closed-loop validation process. Specialised training for all staff handling cold-chain medicines is essential.

📕 Risk notice

Any cold-chain interruption could cause an entire batch of expensive biological products or vaccines to become ineffective, resulting in substantial financial loss. More seriously, using ineffective medicines could cause irreversible harm to patients. Regulators apply a zero-tolerance policy to cold-chain management deficiencies. Failure to provide complete, uninterrupted temperature records is a serious breach that may be sufficient grounds for licence suspension or revocation.

Q311 · 在日常操作中，如果发生了与SOP不符的“偏差”（Deviation），正确的处理流程是怎样的？独立链接

A deviation is any unforeseen event that departs from an approved instruction or established standard, such as an SOP. A mature QMS must have a clear deviation-handling procedure. The process begins when any employee who identifies a deviation reports it immediately. The deviation must then be documented in detail and initially assessed to determine its potential impact on product quality. Depending on the level of impact, immediate control measures, such as quarantining the relevant products, may be necessary. The key step is root cause analysis to establish why the deviation occurred. Based on the analysis, implement corrections/corrective action to address the current problem and preventive action (part of CAPA) to prevent similar issues from recurring. The entire process, from identification through to closure, must be fully documented.

📘 Regulatory basis

The Good Distribution Practice (GDP) for Medicinal Products requires all events that deviate from established procedures to be recorded and investigated. Any significant deviation that may affect the quality of medicines must be thoroughly investigated, and effective corrective and preventive action must be taken, with all actions documented.

📗 Drew Tang's recommendations

We encourage clients to establish a “blame-free” reporting culture that encourages employees to report deviations proactively rather than hide them. Treat deviations as opportunities to improve the system. When conducting root cause analysis, do not stop at “human error”; investigate whether there are systemic causes such as poorly designed processes, inadequate training or insufficient resources. An effective deviation management system is evidence that the QMS can improve itself.

📕 Risk notice

Systematically ignoring deviations, or dealing superficially with deviation investigations and corrective actions, is a serious compliance deficiency. During an inspection, the regulatory authority will use deviation records to assess the health of your quality system. A high number of recurring deviations without effective preventive measures indicates that your QMS is out of control and may lead to stringent regulatory action.

Q312 · 什么是“变更控制”（Change Control）系统？在药品批发业务中，哪些变更需要通过该系统管理？独立链接

Change control is a formal, systematic procedure for assessing, approving and implementing all changes that may affect medicine quality or GDP compliance. Its purpose is to ensure that changes are carefully considered, justified, risk-assessed and effectively controlled and verified both before and after implementation. Typical changes that should be subject to change control in a medicine wholesale business include replacing a key supplier or carrier, bringing a new warehouse facility or area into use, introducing a new IT system (such as WMS/ERP), making major revisions to key SOPs, and changing a cold-chain packaging arrangement. The change control process generally includes submitting a change request, a joint assessment by multiple departments (such as quality, warehousing and IT), risk analysis, preparation of an action plan, implementation of the change and final effectiveness verification.

📘 Regulatory basis

The Good Distribution Practice (GDP) for Medicinal Products requires an effective change control system to be established and operated. All changes to processes, equipment and facilities should undergo a risk assessment before implementation. The approval and implementation of changes must be documented to demonstrate that they have been appropriately managed.

📗 Drew Tang's recommendations

The key to change control is “planning in advance”, not “remedying problems afterwards”. We recommend that clients establish a cross-functional Change Control Board (CCB) to review major change requests. Even seemingly minor changes should be assessed for their cumulative effects. A good change control system is not only a compliance requirement but also an effective management tool for orderly business development and for preventing one problem from being replaced by another.

📕 Risk notice

Arbitrary changes made without approval or assessment are a serious failing in quality management. For example, replacing the refrigerant pack brand used in cold-chain packaging without validation may cause temperatures to exceed limits during transit. If an inspection finds a major change without corresponding change control records, inspectors will seriously question your management capability and compliance awareness.

Q313 · 作为批发商，我应如何对我的客户（如药房、诊所）进行资质审核，以确保合法销售？独立链接

Under GDP requirements, medicine wholesalers are responsible for ensuring that their products are sold only to entities or individuals with the legal qualifications and authorisation to procure and sell medicines. This is a key “gatekeeper” duty intended to prevent medicines from entering illegal channels. Your customer qualification procedure must be clearly set out in an SOP. Before supplying a new customer for the first time, you must obtain and verify its Business Registration (BR) certificate and relevant licences for dealing in medicines (such as an Authorised Seller of Poisons licence for a pharmacy or a doctor’s practising licence). You must retain copies of these documents and recheck them periodically (for example, annually) to ensure that the qualifications remain valid. For every sales order, you should verify that the recipient is an approved customer.

📘 Regulatory basis

The Good Distribution Practice (GDP) for Medicinal Products expressly requires wholesalers to take measures to ensure that medicines are supplied to entities with appropriate authorisation. In addition, the Pharmacy and Poisons Ordinance (Cap. 138) imposes strict legal restrictions on supplying certain medicines to unauthorised persons.

📗 Drew Tang's recommendations

We recommend that you establish a “qualified customer master data” file, flagging customers’ qualification status and expiry dates in your ERP or sales system. This enables systematic automated checks at the order placement stage. For medicines with a risk of misuse, pay particular attention to unusual order frequency or quantities. Communicate clearly with your sales team that verifying customer qualifications is their primary responsibility, not merely meeting sales targets.

📕 Risk notice

Selling pharmaceutical products to unqualified individuals or companies is an extremely serious offence. It not only breaches GDP but may also constitute a criminal offence, resulting in a heavy fine for the company and a risk of imprisonment for the person responsible. Regulators adopt a zero-tolerance approach to such conduct. An inadequate customer qualification system is effectively an open invitation to illegal pharmaceutical trading.

Q314 · 一个全面的员工培训体系应包含哪些内容，才能满足GDP的要求？独立链接

Staff are the most active and one of the most critical elements of the quality management system. An effective training system is essential to ensure that all staff understand and are competent to perform their duties. GDP requires the training system to cover all staff involved in activities relating to medicine wholesaling. It should cover at least: 1. induction training on basic GDP concepts, the company's quality policy and personal hygiene requirements; 2. specific training on job responsibilities and relevant SOPs; 3. specialised training for staff in specific roles (such as those handling cold-chain products, dangerous goods or controlled medicines); and 4. regular GDP updates and refresher training. Detailed records of all training must be maintained, including the date, content, trainer and trainee signatures. The effectiveness of training should also be assessed regularly.

📘 Regulatory basis

Chapter 2, “Personnel”, of the Good Distribution Practice (GDP) for Medicinal Products expressly requires all staff to receive initial and ongoing training appropriate to their duties. Training effectiveness should be assessed, and all training records retained. Personnel in key roles must have adequate competence and experience.

📗 Drew Tang's recommendations

Training should not consist merely of ‘reading out the SOP’. We recommend using a variety of training methods, such as classroom explanations, practical demonstrations, case studies and knowledge tests, to improve staff engagement and understanding. Establish an annual training plan and adjust its content as needed in response to internal audits, deviation investigations or regulatory updates. Organise training records into an individual ‘training file’ for each employee to facilitate management and retrieval.

📕 Risk notice

Insufficient training or incomplete training records are common deficiencies found during regulatory inspections. If an employee cannot answer inspectors’ questions about their duties or the relevant SOPs, this will seriously undermine inspectors’ confidence in your company’s management. If an investigation into a quality incident finds that it was caused by inadequate staff training, the company’s liability will be increased.

Q315 · 药品仓库的害虫控制（Pest Control）有哪些具体要求？可以自己处理吗？独立链接

Pests (such as rodents, cockroaches, ants and birds) pose a direct threat to the packaging and quality of medicines. An effective, ongoing pest control programme is therefore a basic GDP requirement for storage facilities. The programme should be based on a risk assessment of the warehouse environment. Specific requirements include: 1. Keep the area around the warehouse clean and remove potential breeding sites; 2. Ensure the warehouse structure is in good condition and seal all possible pest entry points (such as gaps around doors and openings for pipes); 3. Strategically place monitoring and control devices, such as rodent traps and insect glue boards, inside and outside the warehouse, and prepare a placement plan; 4. Inspect these devices regularly and record inspection findings and any pests caught; 5. Manage waste strictly and remove it promptly. As pesticides may themselves contaminate medicines, open toxic baits and spray pesticides should be avoided in medicine storage areas.

📘 Regulatory basis

Chapter 3, “Premises and Equipment”, of the Good Distribution Practice (GDP) for Medicinal Products requires storage areas to be kept clean, with appropriate procedures for cleaning up any spillages, and an effective pest control programme to be implemented. Pest control substances must not themselves pose a contamination risk to medicines.

📗 Drew Tang's recommendations

We strongly recommend outsourcing pest control to a professional and reputable third-party company. Such companies have the expertise, equipment and compliant pesticides to provide systematic services and complete documentation (such as service reports, site plans showing treatment points and pesticide safety data sheets). This is more efficient, safer and easier to demonstrate as compliant during regulatory inspections than handling it yourself. You should sign a contract with the service provider and review its service reports regularly.

📕 Risk notice

Signs of pest activity in a warehouse, such as droppings or gnaw marks, indicate a serious failure to meet hygiene standards. If pests damage the integrity of medicine packaging, the entire batch may be regarded as contaminated and have to be destroyed. Improper use of pesticides by staff can have consequences worse than the pests themselves if the medicines become contaminated.

Q316 · 如何制定和执行一份有效的仓库清洁与卫生（Cleaning and Sanitation）SOP？独立链接

Keeping the warehouse clean and hygienic is fundamental to preventing cross-contamination of medicines and ensuring appropriate storage conditions. An effective cleaning SOP should be highly practical. It should clearly specify: 1. The scope of cleaning: all areas, including floors, shelving, walls, ceilings and equipment surfaces; 2. Cleaning frequency: for example, floors daily and shelving weekly; 3. Cleaning tools and agents: specific types must be identified, and these materials must not contaminate medicines; 4. Detailed cleaning methods and steps: for example, working from top to bottom and from inside to outside; 5. Post-cleaning inspection criteria: achieving a “visibly clean” standard; 6. Cleaning records: a designated person should complete a cleaning log recording the date, time, person carrying out the cleaning and person inspecting it. There should also be a specific procedure for dealing with accidental spills, such as leakage from damaged medicines.

📘 Regulatory basis

The Good Distribution Practice (GDP) for Medicinal Products sets out clear requirements for cleaning storage areas, which must be kept clean and dry and maintained within acceptable temperature limits. Written cleaning procedures and records must be in place to demonstrate that cleaning has been carried out effectively.

📗 Drew Tang's recommendations

Assign cleaning responsibilities to specific personnel and train them on the relevant SOPs. Design cleaning logs to be clear and easy to complete. We recommend periodically validating cleaning effectiveness, for example by using ATP bioluminescence testing to quantify surface cleanliness, although this is not mandatory. Importantly, management should demonstrate its commitment to cleanliness and hygiene through inspections and foster a positive workplace culture.

📕 Risk notice

A dirty and untidy warehouse is the most obvious sign of GDP non-compliance. Dust, stains and accumulated rubbish can all become sources of microbial growth and cross-contamination. During a regulatory inspection, if cleaning logs are missing or clearly inconsistent with the actual conditions on site, inspectors may conclude that your SOPs and quality system exist only “on paper” and are not being implemented.

Q317 · 当客户退回药品时，我应该如何处理？退回的药品可以重新销售吗？独立链接

Returns are a high-risk area and must be governed by a strict SOP. First, all returned drugs must be identified immediately and quarantined in a dedicated, secure returns area to prevent them from inadvertently re-entering saleable stock. An authorised member of the quality department must then carefully assess the returned drugs to determine their final disposition. Only if very strict conditions are met may drugs be considered for return to saleable stock. These conditions include the drugs remaining in their original, unopened packaging; storage conditions having been maintained throughout (for example, with evidence that the cold chain was not interrupted); sufficient remaining shelf life; and inspection and approval by a qualified person. Any drugs that do not meet these conditions must be destroyed.

📘 Regulatory basis

Chapter 6, “Complaints, Returns, Suspected Falsified Medicinal Products and Medicinal Product Recalls”, of the Good Distribution Practice (GDP) for Medicinal Products sets out detailed requirements for handling returns. It expressly states that returned medicines must undergo a risk assessment before their disposition is decided, and that the conditions for returning them to stock for sale are very stringent.

📗 Drew Tang's recommendations

Our core recommendation is to take the most conservative approach to returns: “When in doubt, destroy.” Reselling returned medicines carries a very high risk, as it is difficult to be absolutely certain about the storage conditions they were kept in after leaving your warehouse. It is vital to keep clear records of the receipt, assessment and disposal of returns. Strictly reserve decisions on handling returns to the quality department, so that sales pressures do not affect quality judgements.

📕 Risk notice

Incorrectly returning non-conforming returned medicines to stock for sale poses an extremely serious quality and safety risk. If the medicines have deteriorated or have been stored improperly, they could harm patients. If discovered by regulators, this will be regarded as a serious GDP breach and may result in your licence being suspended or revoked immediately.

Q318 · 如果在我的库存中发现或收到客户报告的“伪冒药品”（Falsified/Counterfeit Medicines），我该怎么办？独立链接

Discovery of suspected counterfeit medicines is an emergency requiring immediate and decisive action. Your SOP must include a clear emergency procedure. First, immediately segregate all medicines suspected of being counterfeit from stock and place them in a secure, clearly marked quarantine area to prevent further distribution. Second, notify management immediately and report the matter without delay to the Drug Office, Department of Health, Hong Kong. At the same time, check your procurement records to identify the source of the suspect medicines and notify your supplier. You must fully cooperate with the Department of Health’s investigation and provide all relevant documents and information. Do not dispose of the suspect medicines in any way until you have received clear instructions from the Department of Health.

📘 Regulatory basis

The Good Distribution Practice (GDP) for Medicinal Products sets out clear requirements on this. Licensees must have procedures for responding when falsified medicines are found or suspected to have entered the legitimate supply chain. The key requirements are: isolate, report and cooperate. The Trade Descriptions Ordinance (Cap. 362) also prohibits the sale of goods bearing forged trade marks.

📗 Drew Tang's recommendations

Prevention is the best strategy. Establish a rigorous supplier qualification procedure and purchase medicines only through reputable, authorised channels; this is the first and most important line of defence against counterfeit medicines entering the supply chain. Train your staff to recognise signs of suspicious medicines, such as unusual packaging, incorrect labelling or inconsistent batch numbers. Stay vigilant and never buy stock from unknown sources just because it is cheap.

📕 Risk notice

Selling or possessing counterfeit medicines is a serious criminal offence. Upon conviction, the company may face a substantial fine, and the persons responsible may also be sentenced to imprisonment. Failing to report the matter despite knowing about it, or attempting to cover it up, will only make the legal consequences more serious. In cases involving counterfeit medicines, transparent communication and prompt cooperation with the regulator are the only appropriate course of action.

Q319 · 在QMS中，“数据完整性”（Data Integrity）指的是什么？为何它如此重要？独立链接

Data integrity means the completeness, consistency and accuracy of data. In pharmaceutical regulation, it is commonly summarised by the “ALCOA+” principles: data should be attributable, legible, contemporaneous, original and accurate. The “+” stands for complete, consistent, enduring and available. Paper records and electronic data must both comply with these principles. Data integrity is crucial because all decisions about the quality, safety and efficacy of medicines are based on this data. If the data is unreliable, the entire quality system and all evidence of compliance lose their foundation.

📘 Regulatory basis

Although the term “data integrity” does not appear expressly in every piece of legislation, its principles are embedded throughout GMP and GDP. For example, PIC/S and the World Health Organization (WHO) have both issued dedicated data integrity guidelines, which have become inspection standards for regulators worldwide, including the Hong Kong Department of Health.

📗 Drew Tang's recommendations

We recommend that clients safeguard data integrity through both technology and culture. Technically, use validated electronic systems with audit trail functionality, restrict data amendment permissions, and ensure system security and data backups. Culturally, emphasise to all staff the importance of honest record-keeping, and strictly prohibit data falsification or retrospective “completion” of records. Include data integrity as a dedicated checkpoint in internal audits.

📕 Risk notice

Data integrity is one of the key areas of focus in pharmaceutical regulatory inspections worldwide. Any form of data falsification, deletion or improper amendment, once discovered, will be regarded as serious deception. This will not only result in a failed inspection and severe regulatory penalties, but may also destroy the company’s reputation. Regulators may consequently question the authenticity of all data you have submitted in the past.

Q320 · 我的质量手册（Quality Manual）应该包含哪些核心内容？它和SOP是什么关系？独立链接

The Quality Manual is the “constitution” of the Quality Management System (QMS): a high-level policy document. It outlines the company’s Quality Policy and quality objectives, describes the overall structure and scope of the QMS, and explains how it meets requirements such as GDP. Its core contents should include: 1. A company profile and Quality Policy statement; 2. The scope of the QMS (for example, the products, activities and locations to which it applies); 3. References to applicable regulations and standards (such as GDP); 4. An organisation chart, particularly the responsibilities and authority of quality-related roles; 5. An overview of each core QMS process, such as procurement, storage, distribution and recall, with directions to the relevant SOPs for operational details. The Quality Manual is therefore a top-level document describing “what to do” and “why”, while SOPs are supporting documents that explain “how to do it” in detail.

📘 Regulatory basis

The Good Distribution Practice (GDP) for Medicinal Products requires the quality system to be fully documented. Although it does not require documents to be titled “Quality Manual”, in practice this is the best way to describe the entire QMS and meet the documentation requirements.

📗 Drew Tang's recommendations

Keep your quality manual concise and clear. It should be an easy-to-understand guide, not simply a compilation of all SOPs. A good quality manual enables new staff or external auditors to quickly understand your company’s quality management philosophy and the overall system. It should be approved by senior management to demonstrate the company’s commitment to quality. Update the quality manual promptly when there are significant changes to the QMS, such as organisational restructuring.

📕 Risk notice

A quality manual that is out of date and disconnected from actual operations will give inspectors the impression that your QMS is not being maintained. If the quality policy or organisational structure described in the manual does not reflect reality, this will be an obvious compliance deficiency. Although the manual is not referred to as frequently as operational SOPs, it is the “shop window” for your company’s quality management and must remain accurate and authoritative.

Hong Kong Drug Licence FAQs

Plan Your Hong Kong Pharmaceutical Licensing Project with Drew Tang